Back to results

Stason Pharmaceuticals

Manufacturer

Warning letter

Headquarters

United States of America

Sites

United States of America

Products & Services

Aciclovir

Acyclovir

Anastrozole

API-EXCIPIENT INTERACTION STUDIES

API Synthesis

Aripiprazole

Bicalutamide

Bisacodyl

Blister

Bottles

Calcium Acetate

Capecitabine

Captopril

Carbinoxamine

Clinical Packaging Blister

Clinical Packaging Bottles

Container-API Interactions

Custom Manufacturing

Cyclophosphamide

Cyproheptadine

Cyproheptadine Hydrochloride

Dasatinib

Degradation Pathway Determination

Drug Development

Erlotinib

Excipient-Excipient Compatibility

Excipient Screening

Formulation Optimization and Finalization

Glycopyrrolate

Glycopyrronium Bromide

High Containment Operations

High Potency API Capsules Manufacturing

High Potency API Injectables Manufacturing

High Potency API Tablets Manufacturing

High Potent Biological Drugs Manufacturing

Hygroscopicity Studies

Identity, Quantitation, Potency, Content Uniformity

Imatinib Mesylate

Letrozole

Lot Release & Stability Assessment

Matrix Stability Evaluations

Mefenamic Acid

Mercaptopurina

Mercaptopurine

Method Development and Validation

Methotrexate

Nilutamide

Particle Size/Solubility Studies

Phase Solubility Determination

Photostability of API

Pka Log P Determination

Polymorphism

QC Testing and Stability Monitoring

Repaglinide

Scale Up

Selegiline

Selegiline Hydrochloride

Serialization

Solubility & Stability Evaluation

Sorafenib

Temozolomide